Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 21, 2017 - Issue 8
Submit an article Journal homepage
1,430
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Leucine Rich Repeat Kinase 2: beyond Parkinson’s and beyond kinase inhibitors

Susanna CogoDepartment of Biology, University of Padova, Padua, Italy;School of Pharmacy, University of Reading, Reading, United KingdomView further author information
,
Elisa GreggioDepartment of Biology, University of Padova, Padua, ItalyView further author information
&
Patrick A LewisSchool of Pharmacy, University of Reading, Reading, United Kingdom;Department of Molecular Neuroscience, UCL Institute of Neurology, London, United KingdomCorrespondence[email protected]
View further author information
Pages 751-753 | Received 24 Mar 2017, Accepted 12 Jun 2017, Published online: 22 Jun 2017

References

  • Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595–600.
  • Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607.
  • Paisan-Ruiz C, Lewis P, Singleton A. LRRK2: cause, risk, and mechanism. J Parkinson’s Dis. 2013;3:85–103.
  • Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006;23:329–341.
  • Smith WW, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9:1231–1233.
  • Estrada AA, Sweeney ZK. Chemical biology of Leucine-Rich Repeat Kinase 2 (LRRK2) inhibitors. J Med Chem. 2015;58:6733–6746.
  • Trabzuni D, Ryten M, Emmett W, et al. Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. Plos One. 2013;8:e70724.
  • Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study. Lancet Neurol. 2011;10:898–908.
  • Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46:989–993.
  • Cookson MR, Hardy J, Lewis PA. Genetic neuropathology of Parkinson’s disease. Int J Clin Exp Pathol. 2008;1:217–231.
  • Kestenbaum M, Alcalay RN. Clinical features of LRRK2 carriers with Parkinson’s disease. Adv Neurobiol. 2017;14:31–48.
  • West AB, Moore DJ, Biskup S, et al. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005;102:16842–16847.
  • Steger M, Tonelli F, Ito G, et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016;5:e12813.
  • van der Brug MP, Singleton A, Gasser T, et al. Parkinson’s disease: from human genetics to clinical trials. Sci Transl Med. 2015;7:205ps20.
  • Manzoni C, Denny P, Lovering RC, et al. Computational analysis of the LRRK2 interactome. PeerJ. 2015;3:e778.
  • Lewis PA, Manzoni C. LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal. 2012;5:pe2. Epub 2012/01/19.
  • Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med. 2009;361:2609–2618.
  • Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–1125.
  • Hassin-Baer S, Laitman Y, Azizi E, et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol. 2009;256:483–487.
  • Greggio E, Civiero L, Bisaglia M, et al. Parkinson’s disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation. 2012;9:94.
  • Nichols RJ, Dzamko N, Morrice NA, et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010;430:393–404.
  • Li X, Wang QJ, Pan N, et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson’s disease. Plos One. 2011;6:e17153.
  • Guaitoli G, Raimondi F, Gilsbach BK, et al. Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Proc Natl Acad Sci U S A. 2016;113:E4357–E4366.
  • Fuji RN, Flagella M, Baca M, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med. 2015;7:273ra15.
  • Galatsis P. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016). Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
  • Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15:771–785.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.